Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

• Status: Not yet recruiting
• Trial end date: 2026-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois
• Collaborator: Genentech, Inc.

Criteria

Inclusion Criteria:

• Signed informed consent

• age >/= 2

• ability to comply with protocol in investigators judgement

• diagnosis of: severe VWD type 3, or VWD with VWF antigen, activity or collagen binding 50 U/dl based on historical medical records of study site.

• diagnosis of VWD/hemophilia A defined as VWF:ag, activity or CB <50 U/dl, and mild moderate or severe hemophilia A(defined by ISTH criteria) based on historical medical records of the study site.

• plan to be adherent to emicizumab prophylaxis during the study

• Patient's bleeding phenotype necessitating prophylaxis per treating provider recommendations.

• Patient on current prophylaxis for VWD or VWD/hemophilia A may enroll if they are currently on a ono-emicizumab agent, and if it has been > 18 months since last off-label dose of emicizumab, and are willing to discontinue current prophylaxis.

• For menstruating individuals: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year during the study period. A mensturating individual is considered to be of childbearing potential if they are post-menarchal, have not reached a postmenopausal state (12 continuous months of amenorrhea with no identified cause other than menopause), and have not undergone surgical sterilization (removal of ovaries and/or uterus).

Examples of highly effective contraceptive methods with a failure rate of < 1% per year include proper use of combined oral or injected hormonal contraceptive, bilateral tubal ligation, male sterilization, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion Criteria:

• Patients age <2 years of age.

• Patients with low VWF or non-severe VWD (ie.not meeting the above criteria)

• Other concomitant bleeding disorders including coagulopathy from liver cirrhosis.

• Current treatment with emicizumab or emicizumab therapy in the previous 18 months.

• Previous (in the past 12 months) or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or current signs of thromboembolic disease

• Other conditions (e.g., certain autoimmune diseases, including, but not limited to diseases such as systemic lupus erythematosus, inflammatory bowel disease, and antiphospholipid syndrome) that may increase the risk of bleeding or thrombosis

• Patients who are at high risk for thrombotic microangiopathy (TMA; e.g., have a previous medical or family history of TMA), in the investigator's judgment

• Would refuse treatment with blood or blood products, if necessary.

• Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

• Treatment with any of the following:

An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration before Study Day 1 A non-hemophilia-related investigational drug within the last 30 days or 5 halflives- before Study Day 1, whichever is longer An investigational drug concurrently

• History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection

• Pregnant or lactating, or intending to become pregnant during the study

• Women of childbearing potential must have a negative serum pregnancy test result within 7 days before Study Day 1

• Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment

• Serious infection requiring oral or IV antibiotics within 30 days prior to screening